Stay updated with breaking news from Celtic Atao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First patient dosed with ATA-100 gene replacement therapy for LGMD-R9 On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 Atamyo Therapeutics
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA and European EMA Non-dilutive public
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA and European EMA Non-dilutive public
Company also appoints Sophie Olivier, M.D., Chief Medical Officer, joining co-founders Stephane Degove, Chief Executive Officer, and Isabelle Richard, Ph.D., Chief Scientific Officer Atamyo is a